Jazz Pharmaceuticals (JAZZ) Other Operating Expenses (2010 - 2026)

Jazz Pharmaceuticals' Other Operating Expenses history runs 17 years deep, the most recent figure standing at $183.6 million for Q1 2026.

• In Q1 2026, Other Operating Expenses fell 29.11% year-over-year to $183.6 million; the TTM figure through Mar 2026 stood at $2.0 billion (up 87.85% YoY), while the FY2025 annual figure was $2.1 billion, up 94.44% from the prior year.
• Other Operating Expenses was $183.6 million for Q1 2026 at Jazz Pharmaceuticals, down from $323.3 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $1.2 billion in Q2 2025 to a low of $183.6 million in Q1 2026.
• Historically, Other Operating Expenses has averaged $361.9 million across 5 years, with a median of $279.4 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Other Operating Expenses sank 59.28% in 2023, then soared 346.48% in 2025.
• A 5-year view of Other Operating Expenses shows it stood at $679.8 million in 2022, then tumbled by 59.28% to $276.8 million in 2023, then rose by 3.91% to $287.6 million in 2024, then gained by 12.4% to $323.3 million in 2025, then sank by 43.21% to $183.6 million in 2026.
• The last three Other Operating Expenses figures came in at $183.6 million (Q1 2026), $323.3 million (Q4 2025), and $339.7 million (Q3 2025), per Business Quant data.